Matteo Duca

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Validating HER2 copy number variation assessment by NGS: A comparative analysis with immunohistochemistry and in situ hybridization.

Validating HER2 copy number variation assessment by NGS: A comparative analysis with immunohistochemistry and in situ hybridization.

Journal: Tumori

Published: July 09, 2025

Real-World Outcomes of Molecular Tumor Board Treatment Recommendations.

Real-World Outcomes of Molecular Tumor Board Treatment Recommendations.

Journal: JCO precision oncology

Published: June 11, 2025

Genomic instability and CCNE1 amplification as emerging biomarkers for stratifying high-grade serous ovarian cancer.

Genomic instability and CCNE1 amplification as emerging biomarkers for stratifying high-grade serous ovarian cancer.

Journal: Frontiers in oncology

Published: May 22, 2025

Impact of comprehensive genomic profiling and molecular tumour board on costs and access to tailored therapies: real-world observational study.

Impact of comprehensive genomic profiling and molecular tumour board on costs and access to tailored therapies: real-world observational study.

Journal: BMJ open

Published: May 16, 2025

ICIs Exceptional Long Response in TNBC: Addressing the Issue of Optimal ICIs Duration. Two Cases and Review of the Literature.

ICIs Exceptional Long Response in TNBC: Addressing the Issue of Optimal ICIs Duration. Two Cases and Review of the Literature.

Journal: Cancer reports (Hoboken, N.J.)

Published: April 26, 2025

Impact of molecular tests and precision oncology on patients with advanced thyroid carcinomas in a referral center: the OrienTHYring real-world study.

Impact of molecular tests and precision oncology on patients with advanced thyroid carcinomas in a referral center: the OrienTHYring real-world study.

Journal: ESMO open

Published: February 09, 2025

Is tumour sequencing effective for the identification of germline BRCA1/2 pathogenic variant carriers?

Is tumour sequencing effective for the identification of germline BRCA1/2 pathogenic variant carriers?

Journal: Tumori

Published: September 23, 2024

PROACT 2.0: A new open-source tool to improve patient-doctor communication in clinical trials.

PROACT 2.0: A new open-source tool to improve patient-doctor communication in clinical trials.

Journal: Tumori

Published: April 27, 2024

Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockade.

Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockade.

Journal: Scientific reports

Published: November 06, 2023

Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care.

Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care.

Journal: JCO precision oncology

Published: July 24, 2023

Ascites During Selpercatinib Treatment: Need for a Multidisciplinary Approach.

Ascites During Selpercatinib Treatment: Need for a Multidisciplinary Approach.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: September 15, 2022

Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samples.

Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samples.

Journal: Exploration of targeted anti-tumor therapy

Published: April 29, 2022

Showing 1-12 of 25

Last Updated: 09/26/2026